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Abstract
Purpose The Outcome measures for vascular malformation (OVAMA) group reached consensus on the core outcome
domains for the core outcome set (COS) for peripheral vascular malformations (venous, lymphatic and arteriovenous malformations). However, it is unclear which instruments should be used to measure these domains. Therefore, our aims were
to identify all outcome measurement instruments available for vascular malformations, and to evaluate their measurement
properties.
Methods With the first literature search, we identified outcomes and instruments previously used in prospective studies
on vascular malformations. A second search yielded studies on measurement properties of patient- and physician-reported
instruments that were either developed for vascular malformations, or used in prospective studies. If the latter instruments
were not specifically validated for vascular malformations, we performed a third search for studies on measurement properties
in clinically similar diseases (vascular or lymphatic diseases and benign tumors). We assessed the methodological quality of
these studies following the Consensus-based Standards for the selection of health Measurement Instruments methodology,
and evaluated the quality of the measurement properties.
Results The first search yielded 27 studies, none using disease-specific instruments. The second and third search included 22
development and/or validation studies, concerning six instruments. Only the Lymphatic Malformation Function Instrument
was developed specifically for vascular malformations. Other instruments were generic QoL instruments developed and/or
partly validated for clinically similar diseases.
Conclusions Additional research on measurement properties is needed to assess which instruments may be included in the
COS. This review informs the instrument selection and/or the development of new instruments.
Systematic review registration PROSPERO, 42017056242.
Keywords Vascular malformations · Outcome instruments · Outcome measurement instruments · Patient reported ·
PROMs · Physician reported · Measurement properties · Validity · Reliability · Responsiveness · Interpretability
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Introduction
Vascular malformations are benign congenital anomalies of
the vascular system that are categorized based on the type
of vascular channels involved: arterial, venous, lymphatic or
capillary vessels, singularly or combined [1–4]. The disease
impact varies, including cosmetic concerns, pain and functional impairment, depending on the size and location of the
lesion. Multiple treatment options are available, including
compressive stockings, sclerotherapy and surgery; however,
evidence is lacking to support clinical decision-making.
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In current literature, there is no uniformity regarding the
outcomes that are measured to evaluate treatment effectiveness (‘outcome domains’) and what measurement methods
or tools are used to measure these outcomes (also known as
‘outcome measurement instruments’ or simply‘instruments’.
For this reason, outcomes of different clinical trials cannot
be pooled, which hampers the development of evidencebased guidelines.
The Outcome Measures for VAscular MAlformations
(OVAMA) group initiated the OVAMA project aiming to
develop an international ‘Core Outcome Set’ (COS) for adult
as well as pediatric patients with peripheral congenital soft
tissue vascular malformations for measuring outcomes of
therapeutic interventions globally. A COS is an agreed minimum set of outcomes that should be measured and reported
in all clinical trials of a specific disease or trial population
[5]. In an earlier e-Delphi study, the OVAMA consensus
group reached consensus on the core outcome domains
for patients with venous, lymphatic, and arteriovenous
malformations (VM, LM, and AVM respectively): radiological assessment, physician-assessed location-specific
signs, patient-reported pain, overall severity of symptoms,
health-related quality of life (HRQoL), patient satisfaction
with treatment and outcome, and adverse events (Online
Resource 1). For each unique type of vascular malformation,
specific physician- and patient-reported signs and symptoms
were included separately. Furthermore, recurrence and
appearance were recommended outcome domains based
on the e-Delphi study but require further discussion before
final inclusion in the COS [6]. However, it is unclear which
instruments are most suitable for measuring the core outcome domains in adults and children.
This review, as part of the OVAMA project (Online
Resource 2), aims to identify the outcome domains and
instruments for vascular malformations that were used in
previous prospective studies, and to assess the quality of the
available patient- and physician-reported outcome instruments, to inform the selection process of instruments to
measure the core outcome domains in future studies.

Materials and methods
The OVAMA project was registered at the Core Outcome in
Effectiveness Trials (COMET) database (http://www.comet
-initiative.org/), designed following the Harmonizing Outcome Measures for Eczema (HOME) roadmap, and embedded within the Cochrane Skin Group—Core Outcome Set
Initiative (CSG-COUSIN) [7]. We followed the guidelines
of the PRISMA-P statement [8], the Core Outcome Set—
STAndards for Reporting (COS-STAR) [9], and the COnsensus-based Standards for the selection of health Measurement
INstruments (COSMIN) ‘Protocol for Systematic Reviews
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of Measurement Properties’ [10]. The study protocol was
registered in PROSPERO (42017056242).

Literature searches, study selection and data
extraction
This systematic review consisted of three literature searches
(Online Resource 3), as described below.
All searches were performed with the help of a clinical
librarian. The PubMed function ‘Similar Articles’ and reference lists of all included articles were screened for additional
studies. Study selection and data extraction were performed
by two independent reviewers. Disagreements were resolved
by consensus.
Search 1: identification and description of outcome
domains and instruments used in previously published
studies
In the first search, prospective studies evaluating treatment outcomes in vascular malformations were identified
to collect all outcome domains and instruments that were
previously used. We searched MEDLINE, EMBASE and
CENTRAL for studies measuring treatment effectiveness,
using search terms for peripheral vascular malformations.
We included prospective studies evaluating treatments that
enrolled at least 20 patients (all ages) with all singular and
combined types of vascular malformations. Capillary, visceral, bone and central nervous system vascular malformations were excluded as these were outside the scope of
the OVAMA project. Articles published before 1996 were
excluded, since the current classification and terminology for
vascular anomalies was established in 1996 by the International Society for the Study of Vascular Anomalies (ISSVA)
[11]. Data on study characteristics, outcome domains and
instruments were extracted.
Searches 2 and 3: evaluation of the quality of the identified
outcome measurement instruments
The second search was performed in MEDLINE and
EMBASE to identify development and validation studies
of patient- and physician-reported disease-specific instruments for vascular malformations, using search terms for
vascular malformations and a validated PubMed search filter
for finding studies on measurement properties, developed by
Terwee et al. [12].
The third search aimed to identify development and validation studies of patient- and physician-reported outcome
measurement instruments that were used in previously
published prospective studies on vascular malformations,
as identified in search 1, but were not specifically developed and validated for vascular malformations. To explore
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their potential applicability in vascular malformations, we
additionally searched for studies on measurement properties
in patient populations that share clinical similarities with
vascular malformations, predefined as: ‘benign vascular diseases’, ‘benign lymphatic diseases’ and ‘benign soft tissue
tumors’. The expert group considered these groups of health
conditions to have the greatest similarity to vascular malformations in terms of clinical appearance, signs, symptoms
and potential disease burden. Search terms for the identified
patient- and physician-reported instruments were combined
with terms for the predefined clinically similar diseases, and
the abovementioned PubMed filter for studies on measurement properties [12]. Only studies reporting on at least one
measurement property of an instrument that was developed
for vascular malformations, or for a clinically similar condition but previously used for vascular malformations, were
included. Studies not reporting on measurement properties
and studies focusing on health conditions other than vascular
malformations or the predefined clinically similar conditions
were excluded.
Data on characteristics of the included instruments, study
samples and the study results concerning measurement properties were extracted.

Evaluation of the methodological quality
of the included studies
The methodological quality of the included studies on
measurement properties was evaluated by two authors
independently using the COSMIN checklist (www.cosmi
n.nl) [13, 14]. With this checklist, we evaluated, for each
included study separately, which measurement properties
were investigated (following the COSMIN taxonomy, Online
Resource 4) and if the methods to do so were appropriate.
Several items per measurement property were rated using on
a 4-point rating scale ranging from ‘excellent’ to ‘poor’. The
overall score for each measurement property was determined
by the ‘worst score counts’ principle [15]. As a gold standard
for patient-reported outcome measures is lacking, criterion
validity was not considered. Data on interpretability and feasibility were collected if presented in the included studies.

Two reviewers independently extracted data on the measurement properties from the selected articles and evaluated
methodological quality of the studies. Discrepancies were
discussed with a third reviewer until consensus was reached.

Evaluation of quality of the measurement
properties
Two authors independently evaluated the quality of the
measurement properties by rating the results of the analyses
on measurement properties in each included study based
on the criteria for good measurement properties as recommended by Terwee et al. [16, 17] (Online Resource 5). The
study results were independently rated by two reviewers as
‘positive’ (+), ‘negative’ (−) or ‘indeterminate’ (?) for each
measurement property.

Best evidence synthesis
The best evidence synthesis is aimed at reaching a conclusion about the overall quality of each of the measurement
properties of the included instruments. For this purpose, the
quality assessments of the measurement properties based on
the study results of the included studies were combined and
adjusted for the methodological quality of the studies by
applying levels of evidence as recommended by the COSMIN group [16], taking into account the number of studies,
the methodological quality of the studies and the consistency of the study results on measurement properties across
studies.
For each measurement property, the methodological
quality of the study (poor, fair, good or excellent) and the
direction of the study results of the analyses on this measurement property (negative, indeterminate or positive
result) were combined into the best evidence synthesis
(Table 1): +++, ++, +: positive rating indicating “adequate” measurement property; ?: unknown rating indicating indeterminate measurement property; − − −, − −,
−: negative rating indicating “inadequate” measurement
property; ± : conflicting findings; NI: not interpretable

Table 1  Levels of evidence for the overall quality of a measurement property (www.cosmin.nl) [47]
Level

Ratinga

Criteria

Strong
Moderate

+++ or − − −
++ or −

Limited
Conflicting
Unknown

+ or −
±
?

Consistent findings in multiple studies of at least good quality OR one study of excellent quality
Consistent findings in multiple studies of fair methodological quality OR one study of good
methodological quality
One study of fair methodological quality
Conflicting findings
Only studies of poor methodological quality

a

+ positive/good, ? indeterminate, − negative/poor, ± conflicting ratings
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(due to indeterminate result of analysis); NA: not available. (analysis was not performed for this measurement
property).

Results
Search 1: identification of outcome domains
and instruments
In 26 of the 27 studies identified by search 1 (Fig. 1)
the authors exclusively used outcomes that were recommended or selected as core outcome domains in the
OVAMA e-Delphi study [6], however, inconsistently
across the studies, measuring at least one of the following: adverse events [100% of studies], radiological
assessment [56%], appearance [52%], patient-reported
symptoms including pain [37%], patient satisfaction with
treatment and/or outcome [26%], physician-reported
signs [15%], HRQoL [15%] and recurrence [7%]. In one
study, ‘healthcare costs’ was the primary outcome, categorized under the domain practical issues [4%] [18],
which was not selected as a core domain in the OVAMA
e-Delphy study. All instruments used for each outcome
domain are listed in Table 2. None of these were diseasespecific instruments for vascular malformations. Published ‘named’ instruments were only available for the
assessment of HRQoL. Instruments for other outcome
domains were unnamed questionnaires that were only
created for singular use by the authors of the concerning
study.

Fig. 1  Flowcharts of study selection. Search 1 (left): the identification of instruments previously used in prospective studies on vascular
malformations. Search 2 and 3 (right): the identification of development and/or validation studies of disease-specific instruments for vas-
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Searches 2 and 3: evaluation of the quality
of the identified instruments
The searches for development and validation studies on
instruments used for vascular malformations provided 4446
articles (vascular malformations n = 3170; similar diseases
n = 1276), the major reasons for exclusion were failure to
report on measurement properties and studies investigating unrelated health conditions. Twenty-two studies were
included [19–40] evaluating six different instruments
(Fig. 1), of which there was only one disease-specific instrument for vascular malformations. The other included instruments were four generic instruments developed or partly
validated for other clinically similar diseases (two including
a disease-specific module) and one disease-specific instrument for varicose veins, all previously used in vascular
malformation studies. Characteristics of the selected instruments and study populations are presented in Tables 3 and 4,
respectively. The methodological quality of the studies, the
quality of the measurement properties and the best evidence
synthesis are presented in Table 5. Details on the COSMIN
ratings and the evaluation of the measurement properties per
included study can be found in Online Resource 6.
Lymphatic malformation function instrument (LMF)
The LMF is a disease-specific questionnaire to assess functional and clinical signs and subsequent impact on daily
life in pediatric patients with cervicofacial LMs. We found
strong evidence for adequate content validity [40]. Because
it was not described how missing values were handled, there
was limited evidence for adequate internal consistency, for

cular malformations (II), and development and/or validation studies
for instruments previously used in prospective studies on vascular
malformations (III)

[64]
[64]

PedsQL4.0 Infant Scales

FACIT

Unnamed questionnairea

[41, 50, 51, 56, 59, 60, 65, 68]

[64]
[65–67]

[64]

PedsQL4.0

FACT-G
Patient-reported symptoms VAS

[18]
[18]
[63]
[63]

[49, 50, 52, 56–62]

Physical examination (unstandardised)

EQ-5D
SF-36v2
SF-36v2
SF-10

[52–55]

Physician assessment based on
clinical photographs

[41]

[51]

Questionnaire

CIVIQ-20

[49, 50]

Subjective assessment by patient
(unstandardised)

HRQoL

[48]

Physical examination (unstandardised)

Appearance

References

Instrument

Domain category

LM, VM, AVM

LM, CLVM, LVM
LM, VM

LM, CLVM, LVM

LM, CLVM, LVM

LM, CLVM, LVM

VM
VM
VM
VM

LM

LM, VM, AVM, CVM, CLM,
LVM, Vascular malformations
not specified
LM, VM, AVM, CLM, Vascular
malformations not specified

LM, AVM

VM

LM

Type of malformation(s)

Table 2  All instruments used in prospective studies on vascular malformations, categorized per outcome domain

Estimation of changes in size,
normal anatomical shapes,
appearance, discoloration and/
or texture
HRQoL questionnaire for patients
with chronic venous insufficiency
Generic HRQoL questionnaire
Generic HRQoL questionnaire
Generic HRQoL questionnaire
Parent-completed HRQoL questionnaire intended for children
between ages of 5–18
HRQoL questionnaire for children aged 2–18 years
HRQoL questionnaire for
children ages 1–12 months and
13–24 months
Collection of HRQoL questionnaires targeted to the management of chronic illness
Generic HRQoL questionnaire
100-mm scale to assess pain and/
or swelling
To assess changes in pain, swelling, overall severity of symptoms, functional impairment,
visual-, breathing-, swallowingor speaking problems and/or
limb function

Clinical assessment including
manual measurement of the
size of the lesion in 2 dimensions
Estimation of changes in size or
distortion of normal anatomical
shapes
To assess changes in distortion of
normal anatomical shapes
Estimation of changes in size,
color or cosmetic outcome

Description of instrument

Patient

Patient
Patient

Patient

Patient

Patient

Patient
Patient
Patient
Patient

Patient

Physician

Physician

Patient

Patient

Physician

Assessor

Quality of Life Research (2020) 29:1–17
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Measurement instrument which was vaguely or not specified

Clinical assessment (unstandardised)

[50, 68]

[41, 49, 51, 61, 64, 67, 68, 70,
71]

CT/MRI

VM, AVM

LM, VM, AVM, CLVM, LVM

LM, VM, AVM

To assess overall benefit from
treatment, satisfaction with
cosmetic outcome, global result
and/or acceptanceb
100-mm scale to assess overall
cosmetic outcomeb
Satisfaction expressed by the
patient
To assess changes in swelling,
range of movement and/or
unspecified clinical findings
To assess medical costs of sclerotherapy procedure, hospitalization and follow-up imaging
To calculate increment in medical
cost/QALY gained
To calculate utility from EQ-5D
and time
To assess changes in lesion volume or blood flow velocity
To assess changes in lesion volume, clinical phleboliths and/
or organ compression, bone or
joint deformities
Not reported

Description of instrument

Physician

Physician/Radiologist

Physician/Radiologist

Physician

Patient

Patient

Patient

Assessor

By the authors categorized as ‘satisfaction’, possibly also classifiable under the domain ‘Appearance’ or under ‘Supplementary outcome domains’; LM lymphatic malformation, VM venous
malformation, AVM arteriovenous malformation, CVM capillary-venous malformation, CLM capillary-lymphatic malformation, LVM lymphatic venous malformation, CIVIQ-20 20-item chronic
venous insufficiency quality of life questionnaire, HRQoL health-related quality of life, EQ-5D EuroQuality of life 5-dimensions, VAS visual analog scale, SF-36v2 Short-Form 36 health survey
version 2, SF-10 Short-Form 10 health survey for children, CLVM capillary lymphatic venous malformation, PedsQL4.0 pediatric quality of life inventory 4.0, FACIT functional assessment of
chronic illness therapy; FACT-G functional assessment of cancer therapy general

b

a

Recurrence

[48, 50, 55, 57, 58, 61, 68, 69]

(Color Doppler/Duplex) USG

VM

[18]

Radiological assessment

VM

[18]

Incremental cost-effectiveness
ratio
Utility

VM

[18]

Accounting system

LM, VM, AVM

VM, AVM

VM

Practical issues

[56]

Satisfaction expressed by patient
[50, 51, 56, 68]

[67]

VAS

LM, VM

Physical examination (unstandardised)

[41, 49, 60, 65, 66]

Unnamed questionnairea

Patient satisfaction with
treatment and outcome

Type of malformation(s)

Physician-reported signs

References

Instrument

Domain category

Table 2  (continued)
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Table 3  Characteristics of the identified ‘named’ patient- and physician-reported outcome measurement instruments that were developed or previously used for vascular malformations, for which studies on measurement properties were available
Instrument

Target population

LMF [27, 40]

Cervicofacial lymFunctional impairment
phatic malformations (signs and impacts)

CIVIQ-20 [22, 24–26, CVI
29, 30, 37, 39]
SF-36 [20, 21, 28,
32–36, 38]

EQ-5D [28, 31, 35]

Clinical practice and
research, health policy evaluations and
general population surveys
NR

PedsQL-NF1, adults
[23]

Neurofibromatosis
type 1

PedsQL-NF1, children, adolescents
and young adults
[19]

Neurofibromatosis
type 1

Domains

Physical, psychological and social
impairment, pain
PF, PA, BP, GH, V,
SF, EWB, MH

Mobility, self-care,
usual activities, pain,
anxiety

No. of items

Scoring method

Total score range

12

3-point Likert scale,
ordinal

20

5-point Likert scale,
ordinal

30
0–2, with 0 = best
health and 2 = worst
health
28
0–100, with
100 = worst QoL
and 0 = best QoL
0–100, with 0 = worst NR
QoL and 100 = best
QoL

36

5

74
Physical, emotional,
social, cognitive
functioning, communication, worry,
perceived physical
appearance, pain
and hurt, paresthesia’s, skin irritation,
sensation, movement
and balance, daily
activities, fatigue,
treatment anxiety,
sexual functioning
115
Skin, pain, pain
impact, pain management, cognitive
functioning, speech,
fine motor, balance,
vision, perceived
physical appearance,
communication,
worry, treatment,
medicines, gastrointestinal symptoms

NR

3-point Likert scale,
ordinal

5-point likert scale,
ordinal

3-point likert scale,
ordinal

Recall
period
(days)

Responses fitted into
an equation developed from a regression model which
produces a score
from − 0.59 to 1.00,
with − 0.59 = worst
QoL, 1.00 = best
QoL and 0 = death
0–100, with 0 = worst
QoL and 100 = best
QoL

NR

UD

UD

NR

LMF lymphatic malformation function instrument, CIVIQ-20 20-item chronic venous insufficiency quality of life questionnaire, CVI chronic
venous insufficiency, QoL quality of life, SF-36 Short-Form 36 health survey, PF physical functioning, PA physical aspects, BP bodily pain,
GH general health, V vitality, SF social functioning, EWB emotional well-being, MH mental health, NR not reported, EQ-5D EuroQuality of life
5-dimensions, PedsQL-NF1 pediatric quality of life neurofibromatosis type 1, UD under development

inadequate structural validity, and for inadequate hypotheses
testing. The evidence for test–retest reliability was unknown,
as the analysis was only performed in seventeen patients and
therefore the methodological quality of the study on reliability was poor [27]. Data on interpretability, responsiveness to
changes over time or feasibility were lacking.

20‑item chronic venous insufficiency QoL questionnaire
(CIVIQ‑20)
The CIVIQ-20 is a disease-specific HRQoL questionnaire
for patients with chronic venous insufficiency (CVI), which
was validated in patients with CVI [22, 24–26, 29, 30, 37]

13
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Country

Language version

n

Biemans AAM, 2011 The Netherlands
[39]

Jantet G, 2000 (Sub- Czech and Slovak
set Jantet, 2002) [30]
republics, Hungary,
Poland, Russia and
Spain
Jantet G, 2002 [29]
23 countries from the
European, African,
American and Asian
continents
Spain
Lozano FS, 2002
(Subset Jantet G,
2002) [24]
Erevnidou K, 2004
Greece
[37]
18 countriesa
Launois R, 2010
(Subset Jantet,
2002) [26]
Ozdemir OC, 2016
Turkey
[22]
Dutch

159 100

140 100

53

52.3

45.6

4048 100
Turkish

61.1

50 100

Greek

NR

45.2

5052 100

476 100

45.7

3075 100

Spanish

Czech, Slovak, Hungarian, Polish, Russian and Spanish

29.60%

27.9

18.9

14

NR

20

15.5

NR

NR

50

NR

7

60 100

NR

NR

9

35 100

NR

2 vascular surgery
clinics
Surgical outpatient
clinic

NR

NR

Patients ≥ 18 years old Hospital
with CVI CEAP C
stages C3–C6
New patients who con- Hospital
sulted departments
of dermatology and
vascular surgery for
varicose veins

CVI

CVI

CVI

CVI

CVI with symptoms of NR
heavy legs, cramping
or pain or moderate
functional incapacity
NR
CVI (2 groups: with
and without venous
reflux)

Symptomatic CVI

Cervicofacial lymPediatric hospital vasphatic malformations cular anomalies clinic
Tertiary care centers
Cervicofacial lymand online
phatic malformation,
without previously
complete surgical
resection

Percentage of vascular Mean age (years) Gender (% male) Disease characteristics Setting
malformations or
similar diseases (%)

The 20-item chronic venous insufficiency quality of life questionnaire (CIVIQ-20)
Launois R, 1996 (1) France
French
1001 100
[25]
Launois R, 1996 (2) France
French
934 100
[25]

The Lymphatic Malformation Function Instrument (LMF)
Balakrishnan K,
USA
English
2012 [40]
Kirkham EM, 2015
USA
English
[27]

Author

Table 4  Characteristics of the test populations of the included studies
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Country

233 100
368 100

189 100
179 100

English
English
English
English
Chinese

United Kingdom

Franks PJ, 2003 [36]

Franks PJ, 2006 (1)
United Kingdom
[35]
Qiang cao, 2013 [38] China

Franks PJ, 2006 (2)
[35]

United Kingdom

Euro quality of life 5 domains (EQ-5D)
Iglesias CP, 2005
United Kingdom
[31]
Jull A, 2010 (1) [28] New Zealand

368 100

English

189 100

368 100

English
English

387 100

English

118 100

21

Garratt AM,
USA
1996[32]
Walters SJ, 1999[20] United Kingdom
Jull A, 2010 (2) [28] New Zealand

1746

English

20

United Kingdom

1148

21

76.7 (median)

68

71.6

58

76.7 (median)

78

75 (median)
68

45.8

42.7

47.9

42.7

29.3%

49%

41

NR

29.3%

26.3

33.5
49%

24

33.9

46.1

33.5

Referral letters and
general practitioners

Referral letters and
general practitioners

Referral letters and
general practitioners

Lymphedema of the
lower limb

Chronic venous leg
ulcers
Venous leg ulcers

Community-based district nursing services
Hospital and outpatient
clinic

NR

Outpatient clinic and
general practitioner
Venous leg ulcers
8 community clinics
Venous leg ulcers
Community-based district nursing services
Patients suffering from Hospital and community services
chronic leg ulceration
Lymphedema of the
Hospital and outpatient
lower limb
clinic
Patients first suffering Hospital
from deep venous
thrombosis

Patients suffering
from low back pain,
menorrhagia, suspected peptic ulcer
or varicose veins
Patients suffering
from low back pain,
menorrhagia, suspected peptic ulcer
or varicose veins
Patients suffering
from low back pain,
menorrhagia, suspected peptic ulcer
or varicose veins
Varicose veins

Percentage of vascular Mean age (years) Gender (% male) Disease characteristics Setting
malformations or
similar diseases (%)

Ruta DA, 1994[21]

English

1746

n

United Kingdom

English

Language version

Garratt AM,
1994[33]

The Short-Form 36 (SF-36) health survey
Garratt AM,
United Kingdom
1993[34]

Author

Table 4  (continued)
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a

NR not reported, CVI chronic venous insufficiency, CEAP comprehensive classification system for chronic venous disorders

Argentina, Brazil, Brunei, Czech Republic, Egypt, Hong Kong, Hungary, India, Malaysia, Philippines, Poland, Russia, Singapore, Slovakia, Spain, Sri Lanka, Turkey and Venezuela

Hospital
Patients with neurofibromatosis type
1 between 5 and
25 years and parents
of children ages
5–17 years
NR

Nutakki K, 2013 (2) USA
English
11 100
40.2
[23]
Pediatric quality of life inventory neurofibromatosis type 1 (PedsQL NF1, children, adolescents and young adults)
Nutakki K, 2017 [19] USA
English
90 100
NR

NR

Adults with neurofibromatosis type 1

Children’s Tumor
Foundation sponsored
neurofibromatosis
forum
Hospital, conferences,
online
NR
40.5
Pediatric quality of life inventory neurofibromatosis type 1 (PedsQL NF1, adults)
Nutakki K, 2013 (1) USA
English
10 100
[23]

n
Language version
Country
Author

Table 4  (continued)
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Percentage of vascular Mean age (years) Gender (% male) Disease characteristics Setting
malformations or
similar diseases (%)
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and in (isolated) varicose veins [39]. In CVI, moderate evidence was found for adequate internal consistency and reliability. The evidence for measurement error was rated ‘indeterminate’, as the minimal important change was not defined
[22], although this is crucial for concluding if changes in
score can be attributed to true changes in the construct. For
chronic venous insufficiency, there was moderate evidence
for adequate content validity and structural validity.
The evidence for adequate hypotheses-testing and responsiveness was rated as moderate (CVI) and limited (varicose
veins), as the statistical methods used were suboptimal. Ceiling effects were found in three items, which may limit the
instrument’s ability to detect changes in health. The number
of missing items was low (0–9.4%).
Short‑Form‑36 health survey version 2 (SF36v2)
The SF-36 is a generic HRQoL questionnaire [20, 21, 28,
32–36, 38]. Evidence for adequate internal consistency varied from unknown (venous leg ulcers and lymphedema of
the lower limb) [20, 35, 36], limited (varicose veins) [21,
34] to strong (deep venous thrombosis (DVT)) [38]. The
evidence for adequate reliability was considered limited
for varicose veins and moderate for DVT, as information
on missing items was lacking. The evidence for structural
validity could not be interpreted due to the lack of information about explained variance [34, 38]. Finally, limited to
moderate evidence for adequate responsiveness was found in
lymphedema of the lower limb [35] and varicose veins [32,
33], respectively. There was conflicting evidence for venous
leg ulcers [20, 28, 36], and in DVT the evidence was not
interpretable since predefined hypotheses about the expected
results were lacking [38]. In the studies describing interpretability [20, 35], floor- and ceiling effects were found in three
of eight dimensions. Feasibility aspects were not reported.
EuroQoL‑5‑dimensions (EQ‑5D)
The EQ-5D is a generic HRQoL questionnaire, for which
only 3 validation studies were performed in our target populations. In venous leg ulcers, limited evidence was available
for inadequate hypotheses-testing for construct validity as
no predefined hypotheses were stated for the expected correlations [31], whereas in lymphedema of the lower limb,
limited evidence was found for adequate hypothesis-testing
validity [35]. The evidence for adequate responsiveness
was moderate and limited quality in venous leg ulcers and
lymphedema of the lower limb, respectively, because the statistical methods applied were suboptimal or not appropriate
[28, 31, 35]. No floor- and ceiling effects were found [35].
Feasibility aspects were not reported.
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Table 5  Methodological quality, quality assessment of measurement properties and best evidence synthesis per instrument and per disease
Author, year

Internal consistency

Reliability Measurement
error

Content validity

Structural
validity

The lymphatic malformation function instrument (LMF)
Cervicofacial lymphatic malformations
Excellent (+)
Balakrishnan
K, 2012
[40]
Fair (+)
Poor (+)
Fair (−)
Kirkham
EM, 2015
[27]
+
?
NA
+++
−
Best
evidence
synthesis
The 20-item chronic venous insufficiency quality of life questionnaire (CIVIQ-20)
Chronic venous insufficiency
Fair (?)
Fair (+)
Launois R, Fair (+)
1996 (1)
[25]
Good (+)
Fair (+)
Launois R, Fair (+)
1996 (2)
[25]
Jantet G,
Fair (+)
Fair (+)
Fair (?)
2000 [30]
Jantet G,
Poor (+)
Fair (+)
Poor (?)
2002 [29]
Lozano FS, Fair (+)
Fair (+)
2002 [24]
Fair (+)
Fair (?)
Poor (−)
Erevnidou
K, 2004
[37]
Launois R, Good (+)
Good (+)
Good (?)
2010 [26]
Poor (+)
Fair (+)
Fair (?)
Fair (+)
Ozdemir
OC, 2016
[22]
++
++
NI
++
++
Best
evidence
synthesis
Varicose veins
Poor (+)
Good (?)
Good (?)
Biemans
AAM,
2011 [39]
?
NI
NA
NA
NI
Best
evidence
synthesis
The Short-Form 36 (SF-36) health survey
Varicose veins
Garratt AM, fair (+)
Fair (?)
1993 [34]
Garratt AM,
1994 [33]
Ruta DA,
poor (+)
fair (?)
1994 [21]
Garratt AM,
fair (+)
1996 [32]

Hypotheses
testing

Crosscultural
validity

Responsiveness

NA

NA

Fair (−)
−

Poor (+)
poor (?)
Poor (+)

Poor (+)

Fair (+)

Fair (+)
Poor (?)

Fair (+)

Fair (?)

Poor (?)

Poor (?)

Good (+)

Fair (+)

Fair (+)

Fair (+)

++

+

++

Fair (+)

Good (−)

Fair (+)

+

−−

+

Fair (+)
Fair (+)

Fair (+)

Fair (+)

13
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Table 5  (continued)
Author, year

Internal consistency

Reliability Measurement
error

Content validity

Structural
validity

+
+
NA
NA
NI
Best
evidence
synthesis
Venous leg ulcers
Walters SJ, poor (+)
1999 [20]
Jull A, 2010
(2) [28]
Franks PJ,
poor (+)
2003 [36]
?
NA
NA
NA
NA
Best
evidence
synthesis
Lymphedema of the lower limb
Poor (+)
Franks PJ,
2006 (1)
[35]
?
Best
evidence
synthesis
Deep venous thrombosis
Qiang cao, Excellent (+)
Good (+)
Good (?)
2013 [38]
+++
++
NA
NA
NI
Best
evidence
synthesis
The euro quality of life—5 domain (EQ-5D)
Venous leg ulcers
Iglesias CP,
2005 [31]
Jull A, 2010
(1) [28]
NA
NA
NA
NA
NA
Best
evidence
synthesis
Lymphedema of the lower limb
Franks PJ,
2006 (2)
[35]
NA
NA
NA
NA
NA
Best
evidence
synthesis
Pediatric quality of life inventory neurofibromatosis type 1 (PedsQL NF1, adults)
Neurofibromatosis type 1
Good (+)
Nutakki K, Poor (+)
2013 (1)
[23]
Excellent (?)
Nutakki K, Excellent (+)
2013 (2)
[23]
+++
NA
NA
++
?
Best
evidence
synthesis

13

Hypotheses
testing

Crosscultural
validity

Responsiveness

++

NA

++

Good (+)

Good (−)
Fair (+)
Fair (?)

++

NA

±

Poor (+)

Fair (+)

?

+

Poor (?)
NA

NA

Fair (−)

NI

Fair (+)
Fair (+)

–

NA

Fair (+)
+

++

Fair (+)
NA

+

NA

NA

Fair (+)
+
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Table 5  (continued)
Author, year

Internal consistency

Reliability Measurement
error

Content validity

Structural
validity

Hypotheses
testing

Crosscultural
validity

Pediatric quality of life inventory neurofibromatosis type 1 (PedsQL NF1, children, adolescents and young adults)
Neurofibromatosis type 1
Nutakki K,
Excellent (+)
2017 [19]
NA
NA
NA
+++
NA
NA
NA
Best
evidence
synthesis

Responsiveness

NA

For each measurement property, the methodological quality of the study is reported as ‘poor’, ‘fair’, ‘good’ or ‘excellent’. The ratings of the
study results of the analyses on this measurement property are depicted between brackets as ‘−‘(negative result),’?’(indeterminate result),
‘+’(positive result). These two ratings were combined into the best evidence synthesis: +++, ++, + positive rating indicating adequate measurement property; ? unknown rating indicating indeterminate measurement property; − − −, − −, − negative rating indicating inadequate measurement property; ± conflicting findings, NI not interpretable (due to indeterminate result of analysis), NA not available. (analysis was not performed for this measurement property)

Pediatric QoL inventory (PedsQL) ‑NF1, adults
The PedsQL-NF1 is a disease-specific HRQoL questionnaire for patients with neurofibromatosis type 1 [23]. There
was strong evidence for adequate internal consistency and
moderate evidence for adequate content validity. Evidence
for structural validity is unknown because no explained variance was presented in the included study [23]. Evidence
for adequate hypotheses-testing validity was rated limited,
as hypotheses were formulated in retrospect and not predefined. Feasibility, measured by the percentage of missing
responses was 4.8% for all subscales [23]. Interpretability
was not assessed.
PedsQL‑NF1, children, adolescents and young adults
Finally, strong evidence for adequate content validity was
found for the PedsQL-NF1 in children, adolescents and
young adults [19, 23]. Information on other measurement
properties is lacking.

Discussion
All eight outcome domains which were agreed on as the
core outcome domains in the OVAMA e-Delphi study were
assessed in previous prospective studies. However, the outcome domains are not measured consistently throughout
studies, and the instruments used differ markedly as well.
The LMF is the only partially validated disease-specific
instrument available that has been developed as a composite
instrument to assess signs and subsequent impact on daily
activity of living in pediatric patients with cervicofacial
LMs. We found strong evidence for adequate content validity in patients with cervicofacial lymphatic malformations,

which is promising. Yet, future studies in larger samples
should further investigate the internal consistency, reliability, measurement error, structural validity, hypotheses-testing for construct validity, cross-cultural validity and responsiveness of this instrument. The LMF was only published
recently and has not yet been used in prospective studies
[27]. Responsiveness has not been investigated, which is a
crucial aspect when evaluating treatment outcome. A disadvantage is the applicability to a subset of pediatric patients
with cervicofacial LMs only. To broaden its applicability,
further validation of this instrument in other types of cervicofacial vascular malformations would be necessary.
The other included validation studies only concerned
HRQoL instruments that were either generic or developed
for other conditions with clinical similarities to vascular
malformations. Since these instruments were not validated
for vascular malformations, we evaluated the measurement
properties of these instruments in similar clinical populations. The generalizability of these results may be debatable,
but it reflects the best available evidence for exploring which
instruments show the greatest promise for use in vascular
malformation research.
For assessing HRQoL, the SF-36 is a promising measure
for adult patients as its measurement properties are wellinvestigated in diseases that are clinically similar to vascular
malformations. Fewer validation studies in smaller patient
populations with clinical similar diseases were available for
the EQ-5D. The SF-10, FACT-G and FACIT were previously used for vascular malformations, but have not been
validated for this condition or a similar disease. They may
be equally applicable to vascular malformations in terms of
item relevance, comprehensiveness and comprehensibility,
but to date there is no evidence to support this. For children with vascular malformations, the PedsQL was the only
HRQoL instrument used. This instrument was investigated

13
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in children and parents with neurofibromatosis and seems
favorable with regard to the measurement properties analyzed so far [19, 23].
The CIVIQ-20 [41] has adequate measurement properties for patients with venous insufficiency and therefore it
may be worthwhile to further investigate this instrument for
vascular malformations of the lower extremities. This may
also apply to other instruments for similar diseases that have
not yet been used for vascular malformations, like VEINESQoL [42] or the Nottingham Health Profile [43] for varicose
veins. However, the face and content validity of these instruments may be suboptimal for capturing the most important
aspects for patients with vascular malformations, or may
only be applicable to a specific type or location of the vascular malformation.
Interestingly, all included validation studies used classical test theory (CTT) methods, as opposed to item response
theory (IRT). In CTT, measurement properties are assessed
on instrument-level, depending on the items and study sample used, whereas IRT has an item-level focus [44]. The individual validation of items in IRB-based instruments facilitates computer-adaptive testing, in which the items used in
the questioning process adapt to the respondent’s previous
answers [45], and linkage with existing item banks such as
the ‘Patient-Reported Outcomes Measurement Information
System’ [PROMIS] [46].
There were no validation studies available for instruments
measuring the patient- or physician-reported core domains
for vascular malformations pain, overall severity of symptoms, patient satisfaction with treatment and outcome nor
for the recommended domains appearance and recurrence.
Radiologic assessment of the vascular malformation fell outside the scope of this study as we focused on patient/physician-subjective instruments. Further research is required to
determine which radiologic imaging modalities are suitable
for measuring treatment outcome.
It seems necessary to develop a new disease-specific
instrument for vascular malformations, or a disease-specific
attribution module that can be used alongside a generic
instrument, to adequately cover all previously established
core domains. In general, disease-specific instruments are
also more likely to pick up small differences in quality of life
caused by disease burden than the broad generic instruments.

Conclusion
This study provides information on the available evidence
for the quality of patient- and physician-reported outcome
measurement instruments that have been developed or have
previously been used for peripheral vascular malformations. The LMF is the only available disease-specific instrument for assessing signs and life impact in children with
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cervicofacial LMs. The identified generic HRQoL instruments, of which SF-36 (for adults) and PedsQL (for children) seem the most widely applicable, most investigated
and promising in terms of measurement properties, may be
used but it remains unclear if these instruments are responsive to treatment-induced changes in health in patients with
vascular malformations. Further research into measurement
properties may therefore be necessary to assess if the instruments that were identified in this systematic review are suitable for inclusion in the COS. It is likely that new diseasespecific instruments need to be developed to adequately
cover all core domains for vascular malformations.
The results of this review will be used as input for the
future consensus meeting with all stakeholders aiming
to reach consensus on the core outcome measurement
instruments.
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